{"analyses":[{"ciLowerLimit":"0.355","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.542","groupDescription":"Hazard ratio and its 95% CI was based on stratified (IVRS) Cox Regression Model. One-sided p-value was calculated from log rank test and 95% CIs was computed by using Kaplan-Meier estimates.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"< 0.000001","paramType":"Hazard Ratio (HR)","paramValue":"0.439","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.388","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.572","groupDescription":"Hazard ratio and its 95% CI was based on unstratified (IVRS) Cox Regression Model. One-sided p-value was calculated from log rank test and 95% CIs was computed by using Kaplan-Meier estimates.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"< 0.000001","paramType":"Hazard Ratio (HR)","paramValue":"0.471","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.334","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.509","groupDescription":"Hazard ratio and its 95% CI was based on stratified (IVRS) Cox Regression Model. One-sided p-value was calculated from log rank test and 95% CIs was computed by using Kaplan-Meier estimates.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"< 0.000001","paramType":"Hazard Ratio (HR)","paramValue":"0.412","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.365","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.539","groupDescription":"Hazard ratio and its 95% CI was based on unstratified (IVRS) Cox Regression Model. One-sided p-value was calculated from log rank test and 95% CIs was computed by using Kaplan-Meier estimates.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"< 0.000001","paramType":"Hazard Ratio (HR)","paramValue":"0.444","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"44","spread":"44","upperLimit":"49","value":"45"},{"groupId":"OG001","lowerLimit":"87","spread":"87","upperLimit":"128","value":"97"}]}],"title":"mRECIST"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"44","spread":"44","upperLimit":"49","value":"45"},{"groupId":"OG001","lowerLimit":"87","spread":"87","upperLimit":"128","value":"119"}]}],"title":"RECIST 1.1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"379"}],"units":"Participants"}],"description":"TTP was the time (days) from randomization to radiological or clinical disease progression assessed by independent radiological review. Median and 95% confidence interval were reported for the modified response evaluation criteria in solid tumors (mRECIST) and response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) analysis sets. Subjects still alive at the time of analysis were censored at their last date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects received placebo matched to regorafenib coated tablets orally every day for 3 weeks followed by 1 week off treatment plus best best supportive care.","id":"OG000","title":"Placebo"},{"description":"Subjects received regorafenib 160 milligram (mg) (4 \\* 40 mg coated tablets) orally every day for 3 weeks followed by 1 week off treatment plus BSC.","id":"OG001","title":"Regorafenib 160 mg (BAY73-4506)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From date of randomization until 30 days after last study treatment (assessed every 6 weeks until PD; and after 8 cycle assessed every 12 weeks) (approximately 33 months)","title":"Time to Progression (TTP)","type":"SECONDARY","unitOfMeasure":"days"}